Differences in mortality in critically ill elderly patients during the second COVID-19 surge in Europe.
Options
BORIS DOI
Date of Publication
September 23, 2021
Publication Type
Article
Division/Institute
Author
Jung, Christian | |
Fjølner, Jesper | |
Bruno, Raphael Romano | |
Wernly, Bernhard | |
Artigas, Antonio | |
Bollen Pinto, Bernardo | |
Wolff, Georg | |
Kelm, Malte | |
Beil, Michael | |
Sviri, Sigal | |
van Heerden, Peter Vernon | |
Szczeklik, Wojciech | |
Czuczwar, Miroslaw | |
Joannidis, Michael | |
Oeyen, Sandra | |
Zafeiridis, Tilemachos | |
Andersen, Finn H | |
Moreno, Rui | |
Leaver, Susannah | |
Boumendil, Ariane | |
De Lange, Dylan W | |
Guidet, Bertrand | |
Flaatten, Hans |
Subject(s)
Series
Critical care
ISSN or ISBN (if monograph)
1364-8535
Publisher
BioMed Central
Language
English
Publisher DOI
PubMed ID
34556171
Uncontrolled Keywords
Description
BACKGROUND
The primary aim of this study was to assess the outcome of elderly intensive care unit (ICU) patients treated during the spring and autumn COVID-19 surges in Europe.
METHODS
This was a prospective European observational study (the COVIP study) in ICU patients aged 70 years and older admitted with COVID-19 disease from March to December 2020 to 159 ICUs in 14 European countries. An electronic database was used to register a number of parameters including: SOFA score, Clinical Frailty Scale, co-morbidities, usual ICU procedures and survival at 90 days. The study was registered at ClinicalTrials.gov (NCT04321265).
RESULTS
In total, 2625 patients were included, 1327 from the first and 1298 from the second surge. Median age was 74 and 75 years in surge 1 and 2, respectively. SOFA score was higher in the first surge (median 6 versus 5, p < 0.0001). The PaO2/FiO2 ratio at admission was higher during surge 1, and more patients received invasive mechanical ventilation (78% versus 68%, p < 0.0001). During the first 15 days of treatment, survival was similar during the first and the second surge. Survival was lower in the second surge after day 15 and differed after 30 days (57% vs 50%) as well as after 90 days (51% vs 40%).
CONCLUSION
An unexpected, but significant, decrease in 30-day and 90-day survival was observed during the second surge in our cohort of elderly ICU patients. The reason for this is unclear. Our main concern is whether the widespread changes in practice and treatment of COVID-19 between the two surges have contributed to this increased mortality in elderly patients. Further studies are urgently warranted to provide more evidence for current practice in elderly patients.
TRIAL REGISTRATION NUMBER
NCT04321265 , registered March 19th, 2020.
The primary aim of this study was to assess the outcome of elderly intensive care unit (ICU) patients treated during the spring and autumn COVID-19 surges in Europe.
METHODS
This was a prospective European observational study (the COVIP study) in ICU patients aged 70 years and older admitted with COVID-19 disease from March to December 2020 to 159 ICUs in 14 European countries. An electronic database was used to register a number of parameters including: SOFA score, Clinical Frailty Scale, co-morbidities, usual ICU procedures and survival at 90 days. The study was registered at ClinicalTrials.gov (NCT04321265).
RESULTS
In total, 2625 patients were included, 1327 from the first and 1298 from the second surge. Median age was 74 and 75 years in surge 1 and 2, respectively. SOFA score was higher in the first surge (median 6 versus 5, p < 0.0001). The PaO2/FiO2 ratio at admission was higher during surge 1, and more patients received invasive mechanical ventilation (78% versus 68%, p < 0.0001). During the first 15 days of treatment, survival was similar during the first and the second surge. Survival was lower in the second surge after day 15 and differed after 30 days (57% vs 50%) as well as after 90 days (51% vs 40%).
CONCLUSION
An unexpected, but significant, decrease in 30-day and 90-day survival was observed during the second surge in our cohort of elderly ICU patients. The reason for this is unclear. Our main concern is whether the widespread changes in practice and treatment of COVID-19 between the two surges have contributed to this increased mortality in elderly patients. Further studies are urgently warranted to provide more evidence for current practice in elderly patients.
TRIAL REGISTRATION NUMBER
NCT04321265 , registered March 19th, 2020.
File(s)
| File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
|---|---|---|---|---|---|---|---|
| 2021_-_Jung_-_Crit_Care_-_PMID_34556171.pdf | Adobe PDF | 1.61 MB | Attribution (CC BY 4.0) | published |